novo nordisk glp-1 - Search News

News

Novo Nordisk, Ozempic

Novo Nordisk halves Ozempic price to $499 for US patients

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 pharmacies.

The Hill · 16m

Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week,

pharmaphorum · 1d

Novo Nordisk cuts GLP-1 prices for cash buyers

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to a price of $499 for those paying for the drugs out of pocket.

Novo Nordisk, Wegovy and FDA

pharmaphorum · 1d

Novo Nordisk claims first GLP-1 approval in MASH

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be celebrating a first-in-class approval from the FDA for Wegovy in metabolic dysfunction-associated steatohepatitis (MASH).

Contract Pharma · 6h

FDA Approves Novo Nordisk’s Wegovy for MASH

Wegovy is now positioned as the first and only GLP-1 treatment.

Wall Street Journal · 1d

FDA Approves Novo Nordisk’s Wegovy for Liver Disease

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s blockbuster Wegovy medicine to treat a serious fatty liver disease.

9hon MSN

Home Depot disappoints, Novo Nordisk's GLP-1 updates, an AI warning and more in Morning Squawk

Home Depot kicked off this week's string of retailer earnings reports. Novo Nordisk provided two major updates on its ...

Fierce Pharma1d

Novo Nordisk unveils $499 cash-pay Ozempic offering amid continued compounder competition

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

1d

GoodRx CEO discusses GLP-1 deal with Novo Nordisk: What to know

GoodRx (GDRX) stock is skyrocketing after the company struck a deal with Novo Nordisk (NVO) to offer lower prices on GLP-1 ...

3d

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

5don MSN

One in four US adults with diabetes used a GLP-1 drug last year, survey finds

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

1d

Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market

When the FDA took Novo Nordisk and Eli Lilly’s GLP-1 medications off of the drug shortage list, the move should have been a ...

14d

GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and compelling long-term ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results